

ONO PHARMACEUTICAL CO., LTD.

President, Representative Director and CEO: Gyo Sagara
 Securities Code: 4528 at the 1st section of the Tokyo Stock Exchange
 Inquiries: Yukio Tani, Director, Corporate Communications public_relations@ono.co.jp

Revisions of Consolidated Financial Forecasts

ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan) announced revisions of its consolidated financial forecast for the six months ending September 30, 2015 that was originally announced on May 12, 2015.

(1) The revisions of Consolidated Financial Forecasts for the six months ending September 30 (Apr. 1, 2015 – Sep. 30, 2015)

(Millions of yen, except Basic earnings per share)

	Revenue	Operating Profit	Profit before Tax	Profit (Owners of the Parent Company)	Basic earnings per share (Owners of the Parent Company)
Previous Forecast (A)	64,100	7,500	8,800	6,200	¥58.49
Revised Forecast (B)	70,300	14,500	16,000	11,900	¥112.26
Change (B – A)	6,200	7,000	7,200	5,700	-
Change (%)	9.7%	93.3%	81.8%	91.9%	-
(Reference) Results of the previous corresponding period	62,381	3,026	4,697	3,281	¥30.95

(2) Reasons for the revisions

The revenue is forecasted to be ¥70.3 billion (an increase of ¥6.2 billion from the previous forecast). The sales of its long-term listed products continue to be affected by generic drug use promotion policies, but on the other hand, the sales of its new products such as the anti-cancer drug launched last year “OPDIVO Intravenous Infusion” and the rheumatoid arthritis drug “ORENCIA Subcutaneous Injection”, and license revenues are expected to exceed the previous forecast.

Profits are expected to exceed the previous forecast because a certain portion of selling, general, and administrative expenses which were originally scheduled in the first half is postponed until the 3rd quarter or later. For these reasons, operating profit will increase by ¥7.0 billion to ¥14.5 billion, profit before tax will increase by ¥7.2 billion to ¥16.0 billion, and profit attributed to owners of the parent company will increase by ¥5.7 billion to ¥11.9 billion, from the respective previous forecasts.

We are now reviewing its full year forecast and it will be presented at the time of the six months ending results announcement on November 4, 2015.

The financial forecasts and statements contained in this announcement are made based on information that are available as of the date the announcement is made. Actual results may differ materially from those set forth in the announcements due to various uncertain factors.